Sri Kosuri - 11 Jun 2025 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Reporting relationship: Director
Issuer ticker: DNA
Reported as of: 11 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2025, 16:13:06 UTC
Prior SEC filing: 08 Nov 2024
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Karen Tepichin, Attorney-in-Fact

Key filing fact

Sri Kosuri filed Form 4 for Ginkgo Bioworks Holdings, Inc. (DNA) on 13 Jun 2025.

Key facts

This page summarizes Sri Kosuri's Form 4 filing for Ginkgo Bioworks Holdings, Inc. (DNA).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 13 Jun 2025, 16:13.

Change

Previous filing in this sequence was filed on 08 Nov 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002043887 Primary reporting owner

Kosuri Sri

Relationship: Director
Address: C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, BOSTON
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Signature date: 13 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNA transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +24,067
Change %
Price
Shares after: 24,067
Date: 11 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNA transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -24,067
Change %: -100%
Price
Shares after: 0
Date: 11 Jun 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 24,067
Exercise price: $0.000000
Footnotes: F1, F2

DNA transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +34,375
Change %
Price: $0.000000
Shares after: 34,375
Date: 12 Jun 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 34,375
Exercise price: $9.29
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Footnote F2

In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on November 6, 2024 vested in full in Class A shares on June 11, 2025, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.

Footnote F3

In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 12, 2025, the option shall vest and become exercisable in substantially equal installments on each of the first three anniversaries of the date of grant, such that the option shall be fully vested on the third anniversary of the date of grant, subject to the Non-Employee Director continuing in service as a Non-Employee Director through each such vesting date.